RNPA1000產(chǎn)品描述:RNPA1000 is an attractive antimicrobial development candidate; RnpA inhibitor.IC50 value:Target: RnpA inhibitorThe antibiotic vancomycin and a novel Staphylococcus aureus RnpA inhibitor under pre-clinical development, RNPA1000, were included in these studies. Rheological testing characterized the workability of the glass polyalkenoate cement over a range of powder-to-liquid ratios and polyacrylic acid concentrations and revealed that the most suitable powder-to-liquid ratio was 2/1.25 with 40 wt% polyacrylic acid. Loading glass polyalkenoate cement with either 20-30% RNPA1000 or vancomycin prevented bacterial growth. However, longer incubations allowed for Staphylococcus aureus colonies to form near the vancomycin-infused cement, indicating that vancomycin may not be suitable for long-term biofilm inhibition in comparison to RNPA1000. 公司介紹:MedChemExpress(MCE)專注于各種抑制劑、激動劑、API及化合物庫,總部位于美國新澤西,分別在瑞典和上海設(shè)有歐洲區(qū)子公司和亞洲區(qū)總代理,營銷網(wǎng)點遍及全球20多個國家地區(qū)。MCE經(jīng)過多年努力已成為全球生物活性小分子領(lǐng)域的一流供應(yīng)商, 產(chǎn)品涵蓋癌癥、神經(jīng)科學(xué)、抗感染、表觀遺傳學(xué)等20個熱門研究領(lǐng)域,PI3K、MAPK等近千個細分靶點,超過4000個活性小分子化合物現(xiàn)貨,以及GPCR、API、離子通道等超過20種不同類型的化合物庫,同時提供從毫克到千克的專業(yè)定制合成服務(wù)。 MCE 對每批產(chǎn)品都進行嚴格的LCMS和NMR檢驗,其產(chǎn)品已被全球近萬名客戶廣泛使用并發(fā)表大量文章、專利; MCE 定期增加各領(lǐng)域熱門抑制劑、激動劑,不斷擴增已有化合物庫,以滿足最新的科研需求; 數(shù)千種產(chǎn)品在上海有充足備貨,24-48小時內(nèi)送達客戶; 大量產(chǎn)品提供免費試用裝;已為全球多個知名企業(yè)、院校構(gòu)建各種定制型化合物庫。 產(chǎn)品鏈接:www.medchemexpress.cn/rnpa1000.html |
RNPA1000研究進展
發(fā)布日期:2017-11-01 瀏覽次數(shù):0
核心提示:a href=https://www.medchemexpress.com/RNPA1000.htmlRNPA1000/a產(chǎn)品描述:RNPA1000 is an attractive antimicrobial developme
- 下一篇:TP-0903研究進展
- 上一篇:BLU9931研究進展
行業(yè)動態(tài)
更多...
- ATN-161 (trifluoroacetat 11-06
- AZM475271研究進展 11-06
- AVN-944研究進展 11-06
- Ascomycin研究進展 11-06
- β-Lapachone研究進展 11-06
- Anidulafungin研究進展 11-06
- Amsacrine (hydrochloride 11-06
- Amsacrine研究進展 11-06
- Uramustine研究進展 11-06
- Exherin (trifluoroacetat 11-06